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Raltegravir shows marked pharmacokinetic variability in patients, with gastrointestinal pH and divalent-metal binding being
potential factors. We investigated raltegravir solubility, lipophilicity, pKa, and permeativity in vitro to elucidate known interac-
tions with omeprazole, antacids, and food, all of which increase gastric pH. Solubility of raltegravir was determined at pH 1 to 8.
Lipophilicity of raltegravir was determined using octanol-water partition. Raltegravir pKa was determined using UV spectros-
copy. The effects of pH, metal salts, and omeprazole on the cellular permeativity of raltegravir were determined using Caco-2
monolayers. Cellular accumulation studies were used to determine the effect of interplay between pH and ABCB1 transport on
raltegravir accumulation. Samples were analyzed using liquid chromatography-tandemmass spectroscopy (LC-MS/MS) or scin-
tillation counting. Raltegravir at 10 mMwas partly insoluble at pH 6.6 and below. Raltegravir lipophilicity was pH dependent
and was reduced as pH was increased from 5 to 9. The pKa of raltegravir was 6.7. Raltegravir cellular permeativity was heavily
influenced by changes in extracellular pH, where apical-to-basolateral permeativity was reduced 9-fold (P< 0.05) when apical
pH was increased from 5 to 8.5. Raltegravir cellular permeativity was also reduced in the presence of magnesium and calcium.
Omeprazole did not alter raltegravir cellular permeativity. Cellular accumulation of raltegravir was increased independently by
inhibiting ABCB1 and by lowering extracellular pH from pH 8 to 5. Gastrointestinal pH and polyvalent metals can potentially
alter the pharmacokinetic properties of raltegravir, and these data provide an explanation for the variability in raltegravir expo-
sure in patients. The evaluation of how divalent-metal-containing products, such as multivitamins, that do not affect gastric pH
alter raltegravir pharmacokinetics in patients is now justified.
Raltegravir, the first licensed integrase inhibitor for treatmentof HIV, has potent in vitro and clinical activity (22). The pri-
mary route of raltegravir metabolism is glucuronidation via UDP
glucuronosyltransferase 1A1 (14), and the drug is not a substrate
or inhibitor of the major cytochrome P450 enzymes (12). How-
ever, there are known drug interactions involving UGT1A1 which
may alter raltegravir plasma exposure. Atazanavir inhibits
UGT1A1, causing an increase in raltegravir exposure (4), and ri-
fampin mediates induction of UGT1A1, causing a decrease in
raltegravir exposure (27). In addition, raltegravir is a weak sub-
strate for the drug transporters ABCB1, SLC22A6, and SLC15A1
and also inhibits SLC22A6 in vitro (18). Marked inter- and in-
trapatient variability in raltegravir plasma exposure exists, and the
relationship between the pharmacokinetics (PK) and pharmaco-
dynamics (PD) of the drug remains poorly understood (7).
The pH of the gastrointestinal (GI) tract is an important factor
in the absorption of many drugs, potentially altering drug release,
solubility, chemical stability, charge state, and/or intestinal per-
meativity (5). Ionic drugs with a pKa within the physiological pH
range are susceptible to alterations inGI pHbecause drugswith an
ionic charge are less able to permeate the intestine wall without
active transport. In healthy volunteers, raltegravir area under the
curve (AUC),maximumplasma concentration (Cmax) andplasma
concentration 12 h after dosing (C12) increased 3.1-, 4.2-, and
1.5-fold, respectively, following 5 days of 20 mg omeprazole once
daily (13); higher solubility at increasing pHwas postulated as the
mechanism of interaction (2). However, GI pH was not directly
measured in that study, and there are no published data showing
the effect of pH on raltegravir solubility in vitro. In a similar study
using HIV-infected patients, raltegravir geometric mean ratios
(GMR) for AUC, Cmax, and C12 were 1.4-, 1.5-, and 1.2-fold
higher, respectively, following 5 days of 20 mg omeprazole once
daily and 1.5-, 1.6-, and 1.1-fold higher, respectively, following a
single dose of 20 mg famotidine (24). HIV-infected patients, par-
ticularly those with advanced disease progression, have higher
gastric pHs than uninfected individuals (25), and thismay explain
why acid-reducing agents showed less impact on raltegravir PK in
HIV-infected patients in the study by Rhame et al. (24).
After ingestion of a meal, gastric pH is briefly elevated due to
the buffering and diluting effect of the food (5). The extent of
gastric pH increase and the rate at which pH is lowered to fasting-
state levels depend on the volume of the food, the ability of the
food to stimulate gastric acid secretion, and the rate of gastric
emptying. Other factors, such as the fat and protein content of
food, are also important. In a steady-state food effect study using
healthy subjects, alterations in raltegravir exposure from a fasting
state were shown for low-fat (GMRof AUC,Cmax, andC12 of 0.54,
0.48, and 0.86, respectively), medium-fat (GMR of AUC, Cmax,
and C12 of 1.13, 1.05, and 1.66, respectively), and high-fat (GMR
of AUC, Cmax, and C12 of 2.11, 1.96, and 4.13, respectively) meals
(1). However, that study concluded that the effect of food was not
clinically significant and recommended that raltegravir can be
taken without regard to food.
Integrase strand transfer inhibitors work by chelating magne-
sium ions at the integrase enzyme active site, thus preventing the
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insertion of viral DNA into the host cell’s DNA (8). Therefore,
binding with free magnesium (and possibly other polyvalent cat-
ionicmetals) in the GI tract is likely to alter raltegravir absorption.
Indeed, interactions between integrase inhibitors and metal-con-
taining products have been investigated. Raltegravir C12 and time
to Cmax (Tmax) were reduced by 67% and 1.75 h, respectively,
when raltegravirwas takenwith an antacid containingmagnesium
and aluminum, although the AUC andCmax were not significantly
altered (15). Importantly, 75% of subjects taking antacids had a
raltegravir C12 lower than 15 ng/ml (i.e., the 95% inhibitory con-
centration [IC95] of raltegravir in 50% human serum). We hy-
pothesized that this interactionmay bemediated by an increase in
raltegravir solubility with increased pH (decreasing the Tmax) and
binding of raltegravir to the metal ions in the antacid (decreasing
C12).
This study aimed to establish in vitro the solubility, lipophilic-
ity, and pKa of raltegravir using a range of buffered pH solutions
and solvents. The impact of pH,metal cations, and omeprazole on
raltegravir transcellular permeativity across an in vitro model of
absorption were also determined. Raltegravir is a substrate of
ABCB1 in vitro (18), and the interplay between pH and ABCB1
transport was investigated in cellular accumulation assays to as-
certain whether active transport of raltegravir by ABCB1 was in-
fluenced by pH.
MATERIALS AND METHODS
Chemical reagents and materials. Caco-2 cells were purchased from the
European Collection of Cell Cultures (Salisbury, United Kingdom).
Raltegravir potassium salt and [3H]raltegravir were gifts from Merck
(Whitehouse Station,NJ). Lopinavir was a gift fromAbbott (Chicago, IL).
[3H]lopinavir was purchased from Moravek Biochemicals (Brea, CA).
Tariquidar was purchased from Xenova (Sloane, United Kingdom). Ace-
tonitrile was purchased from J. T. Baker (Deventer, Holland). [14C]man-
nitol was purchased from American Radiolabeled Chemicals (St. Louis,
MO). All other reagents were obtained from Sigma (Poole, United King-
dom).
Creation of buffered pH solutions for solubility, lipophilicity, and
pKa experiments. Stock aqueous solutions were buffered to pH 1 (50mM
potassium chloride plus 134 mM hydrogen chloride), 2 (50 mM potas-
sium chloride plus 13 mM hydrogen chloride), 3 (50 mM potassium hy-
drogen phthalate plus 22.3 mMhydrogen chloride), 4 (50mMpotassium
hydrogen phthalate plus 0.1mMhydrochloric acid), 5 (50mMpotassium
hydrogen phthalate plus 22.6 mM sodium hydroxide), 6 (50 mMmono-
potassium phosphate plus 5.6 mM sodium hydroxide), 7 (50 mMmono-
potassium phosphate plus 29.1 mM sodium hydroxide), 8 (50 mM Tris
hydroxymethyl aminomethane plus 29.2 mM hydrogen chloride), and 9
(50mMTris hydroxymethyl aminomethane plus 5.7mMhydrogen chlo-
ride). These stock solutions were used in experiments or were adjusted
using 1 M hydrochloric acid or 1 M sodium hydroxide to create the re-
quired pH.
Determinationof raltegravir solubility.Raltegravir solubilitywas de-
termined at 1mM and 10mM (estimated range of drug concentrations in
the stomach and duodenum of the gut following raltegravir dissolution)
in a pH range of 1 to 8. Solutions weremixed on amechanical shaker (120
rpm, 37°C, 2 h) and vortexed to allow maximum dissolution of raltegra-
vir. Samples were then centrifuged to pellet undissolved drug (3,000 g,
10 min, 22°C), and the supernatant was carefully removed. Raltegravir
concentrations in the supernatant were determined using liquid chroma-
tography-tandem mass spectroscopy (LC-MS/MS).
Determination of raltegravir lipophilicity. Raltegravir lipophilicity
was determined across a physiologically relevant pH range of 1 to 9 using
the octanol-water shake flaskmethod. The organic solvent usedwas either
1-octanol, which allows hydrogen bonding, or cyclohexane, which does
not allow hydrogen bonding. The aqueous and organic solvents weremu-
tually saturated on a mechanical shaker (240 rpm, 24 h, 22°C) before use.
Raltegravir was added to the aqueous solvent at 10 M (a concentration
ensuring complete solubility in all pH solutions) before the aqueous and
organic solvents were combined in a 1:1 ratio and the mixtures were
shaken for 30 min. Mixtures were centrifuged (800  g, 30 min, 22°C),
and a sample was taken from the aqueous compartment for LC-MS/MS
analysis. The apparent log(P) was calculated as log(Corganic/Caqueous),
where Caqueous is the concentration of raltegravir in the aqueous solvent
and Corganic is the concentration of raltegravir in the organic solvent (es-
timated by deducting raltegravir in the aqueous compartment from the
total amount in the mixture).
Determination of raltegravir pKa. Raltegravir pKa was determined
usingUV spectroscopy. Raltegravirwas prepared in buffered pH solutions
to a final concentration of 8 M (a concentration giving an adequate
signal for quantification). The buffered pH solutions ranged between pH
3.5 and 9.5. Drug solutions were added to UV cells, which were then
placed in a UV spectrophotometer (Perkin Elmer Lambda 25 UV-Vis)
and allowed to acclimatize (25°C, 5 min). Following this, the UV-Vis
spectra were measured between 200 nm and 500 nm. The absorbance
values were recorded at 300 nm (absorbance peak predominant at lower
pH) and 333 nm (absorbance peak predominant at higher pH). For each
pH, the absorbance at 333 nm was divided by the absorbance at 300 nm
and plotted to calculate the pKa.
Cell culture. Caco-2 cells were maintained in cell culture (37°C, 5%
CO2) by passaging at 70% confluence using cell culturemedium (Dulbec-
co’smodified Eaglemedium [DMEM], 15%FCS). The passage number of
the cells used in this study was between 25 and 35. Caco-2 monolayers
were cultured as previously described (18) and were subsequently used to
determine the effects of pH, metal salts, and omeprazole on raltegravir
monolayer permeativity. Briefly, confluent Caco-2 cells were seeded onto
polycarbonate membrane Transwells at a density of 5  105 cells/cm2.
Medium was replaced initially after 24 h and then every 48 h. Plates were
used in the experiments 21 days after seeding. Monolayer integrity was
checked on the day of the experiment using aMillicell-ERS (Millipore) to
determine the transepithelial electrical resistance (TEER) across the
monolayer. A TEER of600 was deemed acceptable. In addition, radio-
labeled [14C]mannitol was added to separate wells on each plate (n 3) to
confirm monolayer integrity. [14C]mannitol samples were analyzed by
liquid scintillation counting (Tri-Carb; Beckman), and plates were used
only if the average apparent permeativity of mannitol was less than 1 
106 cm s1.
Impact of pHon raltegravir permeativity of cellmonolayers.On the
day of study, the TEER was assessed and the medium in each plate was
replaced with the appropriate pH-buffered incubation solutions. The pH
in the basolateral compartments was maintained at pH 7.4 (Hanks bal-
anced salt solution [HBSS] containing 25mMHEPES), and the pH in the
apical compartments was maintained at pH 5, 6, or 6.5 (HBSS containing
10 mM morpholineethanesulfonic acid [MES]), pH 7, 7.4, or 8 (HBSS
containing 25mMHEPES), or pH 8.5 (HBSS containing 10mMTricine).
Compartments were allowed to equilibrate (37°C, 30 min). The incuba-
tion buffer in the apical (for transport in the apical-to-basolateral [A-
to-B] direction) and basolateral (for transport in the basolateral-to-apical
transport [B-to-A] direction) compartments was replaced with the ap-
propriate incubation buffer containing raltegravir (50 M), and plates
were incubated (37°C, 5% CO2). A concentration of 50 M raltegravir,
which has been shown to be nontoxic for Caco-2 cells in previous studies
(18), was used to ensure complete dissolution of drug at all pHs (as pre-
dicted by the solubility data) and to ensure that drug concentrations in
receiver compartments were sufficiently high to be quantifiable by LC-
MS/MS. Samples were taken from the receiver compartments at 0, 30, 60,
90, and 120 min and replaced with fresh incubation buffer of the correct
pH. Samples were analyzed using LC-MS/MS. Results were used to deter-
mine apparent permeativity (Papp; units are 10
6 cm s1) for each direc-
tion and to determine the efflux ratio, which is the ratio of B-to-A Papp to
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A-to-B Papp. Papp was calculated as [(dQ/dt)  v]/(A  C0) (6), where
dQ/dt is the change in drug concentration in the receiver compartment
over time (nM/s), v is the volume in the receiver compartment (ml), A is
the total surface area of the Transwell membrane (cm2), C0 is the initial
drug concentration in the donor compartment (nM), and Papp is the
apparent permeativity (cm/s).
Impact of divalent andmonovalentmetals on raltegravir cellmono-
layer permeativity. On the day of study, the TEER was assessed, and the
medium in each plate was replaced with the appropriate pH-buffered
incubation solution. The pH in the basolateral compartments was main-
tained at pH 7.4 (HBSS without calcium chloride or magnesium sulfate
[H6648; Sigma] containing 25 mM HEPES), and the pH in the apical
compartments was maintained at pH 5 (HBSS without calcium chloride
or magnesium sulfate and containing 10 mM MES) or pH 7.4 (HBSS
without calcium chloride or magnesium sulfate and containing 25 mM
HEPES). In the apical compartments at pH 5, magnesium chloride (1
mM, 10 mM, or 25 mM), magnesium sulfate (25 mM), calcium chloride
(25 mM), or potassium chloride (25 mM) was added. In the apical com-
partments at pH 7.4, magnesium chloride (1, 10, or 25mM)was added. A
maximum concentration of 25 mM was used for magnesium chloride, as
higher concentrations showedCaco-2 cell toxicity (data not shown). Con-
trol apical compartments at pH 5 and pH 7.4 which had no added metal
salts other than those in the original buffer were also used. The basolateral
compartments were maintained at pH 7.4 and had no added metal salts
other than those in the original buffer. A concentration of 1Mwas used
for all test compounds in order to maximize the metal-to-drug ratio.
Lopinavir was used as a negative control, as it is not believed to bind to
metals. The incubation buffer in the apical (for A-to-B transport) and
basolateral (for B-to-A transport) compartments was replaced with the
appropriate incubation buffer containing radiolabeled [3H]raltegravir (1
M, 0.5 Ci/ml) or lopinavir (1 M, 0.5 Ci/ml), and plates were incu-
bated (37°C, 5% CO2). Samples were taken from the receiver compart-
ments at 0 and 30 min and were analyzed by liquid scintillation counting.
The Papp and efflux ratios were calculated as described above.
Impact of omeprazole on raltegravir cell monolayer permeativity.
For induction studies using Transwells, the cell monolayers were incu-
bated with omeprazole (10 M) for the last 3 days of the 21-day mono-
layer maturation. On the day of the experiment, the TEER was assessed,
and the medium in each plate was replaced with warm incubation buffer
(HBSS containing 25 mM HEPES, pH 7.4) and allowed to equilibrate
(37°C, 30 min).
For inhibition studies, the incubation buffer contained omeprazole at
20 M, as lower concentrations are known to inhibit CYP2C9 and
CYP2C19 in vitro (16). The incubation buffer in the apical (for A-to-B
transport) and basolateral (for B-to-A transport) compartments was re-
placed with incubation buffer containing the test substrate raltegravir (1
M) with or without 20 M omeprazole, and plates were incubated
(37°C, 5% CO2). A concentration of 1 M raltegravir was used to avoid
saturation of drug transporters (11). Sampleswere taken from the receiver
compartments at 0 and 60 min and were analyzed by liquid scintillation
counting (Tri-Carb; Beckman). The Papp and efflux ratios were calculated
as described above.
Cellular accumulation.Caco-2 cells were seeded (5 104 cells/ml) on
6-well plates and grown for 5 days to allow plate surface coverage (DMEM
with 15% fetal bovine serum [FBS], 37°C, 5% CO2). Medium was re-
moved, cells werewashedwithwarmHBSS, and themediumwas replaced
with the appropriate pH-buffered incubation solution and allowed to
equilibrate (37°C, 15 min). The pH in the wells was fixed at pH 5 or 6
(HBSS containing 10 mM MES) or pH 7 or 8 (HBSS containing 25 mM
HEPES). The test substrate raltegravir (1M)was added to the wells, and
plates were incubated (37°C, 5% CO2, 10 min). A concentration of 1 M
raltegravir was used to avoid saturation of drug transporters (11). A sep-
arate incubation was undertaken in which cells were preincubated
(DMEMwith 15% FBS, 37°C, 5% CO2) prior to raltegravir addition with
the potent noncompetitive ABCB1 inhibitor tariquidar (300 nM, 30min),
which was also included during the 10 min of raltegravir incubation.
Following incubation, an extracellular sample was removed for analysis,
wells were washed three times with ice-cold HBSS, and 500 l tap water
was added to each empty well to lyse cells. Plates were frozen at 20°C
overnight to aid removal of cells. Plates were thawed, and 500 l acetoni-
trile was added to eachwell to release drug fromprotein. Thewell contents
were transferred to separate 1.5-ml tubes for centrifugation (10 min,
3,000 g, 22°C), and supernatantwas removed. Supernatantwas vacuum
dried and reconstituted in high-performance liquid chromatography
(HPLC)-grade water for LC-MS/MS analysis.
LC-MS/MS analysis. Samples from all studies other than cell accumu-
lation studies could be directly injected into the LC-MS/MS system after
dilution with HPLC-grade water. Samples from cell accumulation studies
were prepared as described above for cellular accumulation method. The
LC-MS/MS system used for sample analysis consisted of a Surveyor au-
tosampler and an LCQDecaXP ion trap detector (Thermo,HemelHemp-
stead, United Kingdom). Chromatographic separation was performed at
30°C on a Fortis C18 3-m column (50 by 2.1 mm [inside diameter];
Fortis Technologies, Neston, United Kingdom). Mobile phases were so-
lution A (95% HPLC-grade water, 5% acetonitrile, 0.05% formic acid)
and solution B (10% HPLC grade water, 90% acetonitrile, 0.05% formic
acid), and the flow rate was 0.4 ml/min. Separation was achieved with a
gradient elution beginning with 80% solution A and 20% solution B.
Solution B was gradually increased to 100% over 0.5 min andmaintained
for a further 2 min. Solution A was increased to 80% over 0.1 min and
maintained for 3.9 min, giving a total run time of 6.5 min. The retention
time of raltegravir was 4.78min, and the lowest limit of quantificationwas
31.25 ng/ml.High quality control (QC) (2,000 ng/ml) had an interday and
intraday accuracy of 98.2% and 97.1%, respectively, and an interday and
intraday precision of 97.0% and 93.1%, respectively. Medium QC (200
ng/ml) had an interday and intraday accuracy of 96.8% and 99.1%, re-
spectively, and an interday and intraday precision of 89.1% and 89.2%,
respectively. Low QC (100 ng/ml) had an interday and intraday accuracy
of 96.5% and 92.8%, respectively, and an interday and intraday precision
of 90.0% and 95.3%, respectively. All QCs gave accuracy and precision
higher than 85%, in accordance with U.S. Food andDrug Administration
(FDA) guidelines (23), and the linear range for raltegravir quantification
was 31.25 to 1,000 ng/ml.
Statistical analysis.Data were analyzed using PASW 18 forWindows.
All data were tested for normality using the Shapiro-Wilk test. An inde-
pendent t test was used to determine significance of normally distributed
data. TheMann-WhitneyU test was used for all other data. A two-tailed P
value above 0.05 was accepted as being statistically significant.
RESULTS
Raltegravir solubility. Figure 1A shows raltegravir solubility over
a range of buffers with pHs from 1 to 8. A concentration of 1 mM
raltegravir was fully soluble across this pH range. However, 10
mM raltegravir was fully soluble only at pH 6.8, 6.9, 7, and 8 and
achieved mean supernatant concentrations of 8.0 mM at pH 6.6,
6.3 mM at pH 6.4, 5.0 mM at pH 6.2, 3.7 mM at pH 6, and around
3 mM at pH 5 and below.
Raltegravir lipophilicity. When cyclohexane was used as the
organic solvent, raltegravir remained predominantly in the aque-
ous compartment (90%) in all pH solutions, whereas using oc-
tanol resulted in low raltegravir concentrations (7%) in the
aqueous compartments of pH 5 or less (Fig. 1B). Therefore, when
octanol was used as the organic solvent, the apparent log(P) of
raltegravir was stable between aqueous pH 1 and 5 but decreased
from 1.06 to 1.29 between pH 5 and 9 (P  0.05) (Fig. 1C). A
negative log(P) is usually associatedwith poor cellmembrane per-
meativity (10).
Raltegravir pKa. Figure 1D shows the relative absorbance at
two wavelengths (333 nm versus 300 nm) as a function of the pH
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of the buffer solution. The most substantial change in the curve
occurs betweenpH6 and 8. If it is assumed that this change in peak
ratios is due to an alteration of the charge state of raltegravir, the
pKa is calculated as pH 6.7.
Impact of pH on raltegravir cell monolayer permeativity.
Figure 2A depicts the apical-to-basolateral raltegravir permeativ-
ity through Caco-2 cell monolayers at various apical pH values.
Increasing the apical pH from 5 to 8.5 decreased the rate and
extent of raltegravir monolayer permeativity in the apical-to-ba-
solateral direction (P  0.05). The Papp and efflux ratio of ralte-
gravir at 60 min incubation are shown in Table 1. Raltegravir
efflux ratio increased 12-fold as apical pHwas increased from 5 to
8.5 (P 0.05).When both apical and basolateral pHswere 7.4, the
efflux ratio was 2.5, suggesting active transport in the basolateral-
to-apical direction. However, reducing apical pH to 6 or below
caused raltegravir permeativity to predominate in the apical-to-
basolateral direction, suggesting that pH has the potential to over-
come the effect of active drug transport.
Impact of divalent andmonovalentmetals on raltegravir cell
monolayer permeativity. All Papp and efflux ratio calculations
were made using samples taken after 30 min of incubation, and
sink conditions were maintained at this time point. A positive
correlation between concentration of magnesium chloride in the
apical compartment and raltegravir efflux ratio is shown in Fig.
2B. When the apical compartment pH was 7.4, the raltegravir
efflux ratio was significantly increased in comparisons of control
wells with no additional metal salt (efflux ratio  1.3) to wells
containing 1 mM (efflux ratio  1.6; P  0.05), 10 mM (efflux
ratio  3.4; P  0.05), or 25 mM (efflux ratio  3.7; P  0.05)
magnesium chloride. The lopinavir efflux ratio was unaltered in
comparisons of control wells with no additional metal salt (efflux
ratio 5.1) to wells containing 25 mM magnesium chloride (ef-
flux ratio  5.4; P  0.83), illustrating that the effect of magne-
sium chloride on raltegravir cellular permeativity was not a result
of general changes in monolayer integrity.
When the apical compartment pH was 5, the raltegravir efflux
ratio was unchanged when control wells with no additional metal
salt (efflux ratio 0.8) were compared to wells containing 1 mM
magnesium chloride (efflux ratio  0.7, P  0.28), but a signifi-
cant increase in efflux ratio was observed with the addition of 10
mM (efflux ratio  1.1; P  0.05) or 25 mM (efflux ratio  1.9;
P 0.05) magnesium chloride. Also, the effects of magnesium in
a different salt form (magnesium sulfate), an additional divalent
metal salt (calcium chloride), and amonovalentmetal salt (potas-
sium chloride) were investigated. The raltegravir efflux ratio was
significantly increased in comparisons of control wells with no
additional metal salt (efflux ratio  0.8) to wells containing 25
mM magnesium sulfate (efflux ratio  1.6; P  0.05) or 25 mM
calcium chloride (efflux ratio  1.2; P  0.05). The efflux ratio
was unaltered when 25 mM potassium chloride was added to
the apical compartment (efflux ratio  0.8; P  0.83). This
supports the hypothesis that divalent metals, but not monova-
FIG1 (A) Raltegravir (RAL) solubility at 1mMand 10mM in a range of pH solutions. Data aremeans standard deviations (SD) (3 experimental replicates).
(B) Partition of raltegravir (10 M) between cyclohexane and water and octanol and water at different pHs. Data are means SD (4 experimental replicates; 3
biological replicates). (C) Apparent log(P) of raltegravir (10 M) using octanol and water at different pHs. Data are means SD (4 experimental replicates; 3
biological replicates). (D) Determination of raltegravir pKa using UV spectroscopy. Data are expressed as relative absorbance at two wavelengths as a function of
the pH of the buffer solution (1 experimental replicate).
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lent metals, have the potential to affect raltegravir cell mem-
brane permeativity.
Impact of omeprazole on raltegravir cell monolayer perme-
ativity. Figure 2C depicts the efflux ratio of 1 M raltegravir
through Caco-2 cell monolayers in the presence and absence of
omeprazole as an inhibitor (20 M) or as an inducer (72 h prein-
cubation with 10Momeprazole). All Papp and efflux ratio calcu-
lations weremade using samples taken after 60min of incubation,
and sink conditions were maintained. In inhibition studies, there
was no significant difference in raltegravir efflux ratio between
control cells and cells coincubatedwith 20Momeprazole (efflux
ratio of 2.7 versus 2.6; P  0.83). Similarly, in induction studies,
there was no significant difference in raltegravir efflux ratio be-
tween control cells and cells preincubated for 72 h with 10 M
omeprazole (efflux ratio of 2.7 versus 2.6; P 0.51).
Impact of pH and ABCB1 inhibition on raltegravir cellular
accumulation. Figure 2D depicts the accumulation of raltegravir
in Caco-2 cells that occurred when various pH buffers were used
and tariquidar was used to inhibit ABCB1. Raltegravir accumula-
tion in Caco-2 cells increased 3.4-fold when the incubation buffer
pHwas decreased from 8 to 5 (P 0.05). This pH-related increase
in raltegravir accumulation was also observed in cells treated with
the ABCB1 inhibitor tariquidar (3.3-fold decrease; P 0.05). In-
hibiting ABCB1 led to increased raltegravir accumulation at pH 5
(1.4-fold; P  0.05), 6 (1.5-fold; P  0.05), and 7 (1.4-fold; P 
0.05) but not at pH 8 (P  0.08). These results suggest that pH
impacts cellular permeativity of raltegravir to a greater extent than
ABCB1 transport and that ABCB1 transport of raltegravir is inde-
pendent of pH.
DISCUSSION
In this study, the influence of pHon raltegravir solubility, lipophi-
licity, and cellular permeativity was investigated. Raltegravir ex-
hibited solubility of less than 10 mM at pH 6.6 and below. It is
likely that the drug obtains a negative charge at higher pH by
deprotonation of the hydroxyl group at the 5 position of the
6-oxo-1,6-dihydropyrimidine ring. This negative charge would
dramatically increase the solubility of the drug in aqueous buffer.
FIG 2 (A) Time course experiment showing A-to-B permeation of raltegravir (RAL; 50 M) obtained with apical buffers with the indicated range of pHs in
Caco-2 monolayers over 120 min. The basolateral pH was maintained at 7.4. Data are means of raltegravir accumulation in the basolateral (receiver) compart-
ment (3 experimental replicates). (B) Efflux ratio of raltegravir (1 M) in Caco-2 monolayers using a range of magnesium chloride concentrations in the apical
compartment. The apical compartment was maintained at pH 5 or pH 7.4, and the basolateral compartment was maintained at pH 7.4. (C) Efflux ratio of
raltegravir (1M) in the presence of omeprazole (inhibitor study; 20M) or with cells preincubated with omeprazole for 3 days (induction study; 10M). Data
in panels B and C are mean efflux ratios (B-to-A/A-to-B)  SD (3 experimental replicates). (D) Accumulation of raltegravir (1 M) in Caco-2 cells at an
extracellular pH of 5 to 8, with and without the ABCB1 inhibitor tariquidar (300 nM). Data are means SD (3 experimental replicates).
TABLE 1 Effect of pH on raltegravir (50 M) permeativity using a
Caco-2 monolayer
pH of apical
compartmenta
Papp (10
6 cm/s)b
Efflux
ratiocA to B B to A
5 27.3 1.2 11.9 1.5 0.4
6 17.6 1.7 13.1 2.3 0.7
6.5 9.2 1.1 14.5 1.5 1.6
7 8.4 1.2 14.5 2.1 1.7
7.4 6.6 0.8 16.4 2.9 2.5
8 3.5 0.5 13.8 0.7 3.9
8.5 2.9 0.3 14.1 1.3 4.9
a The pH of the basolateral compartment was maintained at 7.4.
b Data are means SD for 3 experimental replicates.
c Compared to the efflux ratio at pH 5, all other ratios had a P value of0.05.
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Additionally, raltegravir log(P) was shown to decrease as pH is
increased above 6, presumably due to the introduction of a charge
to the drug. The solubility and lipophilicity data are supported by
our UV spectroscopy study, where raltegravir pKa was calculated
at 6.7. This pKa is located within the pH range that is encountered
by the drug during absorption in the GI tract. This offers us a
convincing explanation of the intra- and interpatient variability of
raltegravir PK in healthy and HIV-1-infected subjects (3).
In experiments assessing raltegravir cellular permeativity,
raltegravir was less able to cross a Caco-2 cell monolayer as the
incubation buffer pH was increased from 5 to 8.5. This is most
likely due to the introduced charge at the active site, preventing
the drug from passing through the phospholipid bilayer of the cell
membrane. Similar results were seen in accumulation studies,
where less raltegravir was present in the cells when the pH was
increased from 5 to 8. ABCB1 inhibition had less impact on ralte-
gravir intracellular concentrations than changes in extracellular
pH. Permeability and accumulation were assessed using raltegra-
vir concentrations from1Mto 50M, and our solubility studies
show that the drug is fully soluble at all pHs at these concentra-
tions. Therefore, the introduction of a charge to raltegravir by
increasing pH could have opposing consequences depending on
the concentration of the drug. At high drug concentrations, the
introduced charge is predicted to increase dissolution and there-
fore absorption. Conversely, at lower concentrations, solubility is
unlikely to be a problem, and therefore the introduced chargemay
reduce the rate of absorption.
In previous clinical studies, coadministration of omeprazole
and famotidine resulted in an increase in raltegravir Cmax (24).
This may result from the predicted increased solubility of ralte-
gravir in the stomach and the duodenum, where drug concentra-
tions would be highest. The C12 of raltegravir was only slightly
higher or unchanged when the drug taken with omeprazole or
famotidine (24). It is tempting to speculate that over time, ralte-
gravir dissolution normalizes in all subjects and the benefit of
increased gastric pH is overcome. Inhibition and induction stud-
ies with omeprazole indicated that there were no direct effects on
raltegravir cellular permeativity, indicating that the effect of
omeprazole most likely results from its pH-altering properties.
Ingestion of a meal has been shown to result in an increase in
gastric pH (5), which would be predicted to increase raltegravir
solubility. However, only high-fat meals have been shown to in-
crease raltegravir exposure, with low-fat meals resulting in a re-
duction (1). It is possible that a high-fat meal may dilute stomach
acid to a greater extent or that the fat in themeal could increase the
solubility of raltegravir.
Raltegravir cellular permeativity decreased in the presence of
the divalent cations magnesium and calcium in the incubation
medium. This decrease was not found when the monovalent cat-
ion potassiumwas used. Raltegravirmay bind to the divalentmet-
als and form a metal-drug complex which is unable to cross the
cell membrane. It is important to note that binding of raltegravir
to a divalent metal (magnesium) is a prerequisite for inhibition of
HIV integrase (17). Antacids containing magnesium caused no
significant change in raltegravir Cmax or AUC but did reduce C12,
resulting in 75% of patients having a C12 less than the IC95 (15).
The impact of antacids may be explained by a combination of the
effects of pH and metal binding. We hypothesize that Cmax re-
mains unchanged while raltegravir solubility improves with in-
creased pH but that absorption is inhibited by magnesium bind-
ing. At later time points, when raltegravir solubility is no longer an
issue, the elevated presence of magnesium in the gut may reduce
the amount of raltegravir being absorbed, thus reducing raltegra-
vir C12. If this is true, coadministration of products containing
polyvalent metal cations that do not alter gastric pH (e.g., multi-
vitamin tablets) would be expected to reduce raltegravir exposure.
This is certainly now worthy of empirical determination.
These data may also have implications for the newer integrase
strand transfer inhibitors elvitegravir and dolutegravir. Elvitegra-
vir and dolutegravir exposure has been shown to be reduced when
these drugs are taken with antacids containing magnesium and
aluminum, with the reduction being less marked when the drug is
taken 2 h before the antacid (19, 21). In healthy subjects, elvite-
gravir and dolutegravir absorption has also been shown to be in-
fluenced by food according to fat content (26, 9), and it is recom-
mended that elvitegravir be taken with food (20). Interestingly,
dolutegravir exposure has also been shown to be moderately re-
duced when the drug is taken with a multivitamin containing
magnesium, calcium, iron, zinc, and copper (19).
In conclusion, the physicochemical properties of raltegravir
are heavily influenced by environmental pH. Both pH and poly-
valent metals have the potential to alter the pharmacokinetics of
raltegravir, and these data help provide a rationale for the variabil-
ity in raltegravir exposure seen in patients. The evaluation of how
divalent metal-containing products, such as multivitamins that
do not affect gastric pH, alter raltegravir pharmacokinetics in pa-
tients is now justified. A comprehensive knowledge of the mech-
anisms that underpin variability in disposition will help optimize
future therapy with raltegravir.
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